News

News
JNJ Press releases

Big Pharma’s Billion-Dollar Scramble to Invest in Start-ups to Fuel Innovation

Read full story
Partner news

Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis

Read full story
JNJ Press releases

Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides‐type cutaneous T‐cell lymphoma, a rare type of skin cancer

Read full story